Adagene Inc wrapped up its $139.73 million initial public offering, selling 7,354,000 American depositary shares at $19 each. The stock opened at $20.40 when trading began Tuesday and skyrocketed by more than 45% in early trading.
How to buy Adagene stock
- Choose a stock trading platform. Use our comparison table or choose from our Top Picks below.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds unto your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – ADAG. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
SoFi Invest
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
eToro
- Easy to use platform with $0 stock trading & no annual fees
- Social trading allows you to copy popular portfolios
- FINDER EXCLUSIVE: Guaranteed $15 bonus when you sign up and deposit $100
tastytrade
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $100 - $2,000 when you open and fund an account with $5,000 to $100,000+
Adagene stock price (NASDAQ: ADAG)
Use our graph to track the performance of ADAG stocks over time.Adagene shares at a glance
Latest market close | $1.55 |
---|---|
52-week range | $0.90 - $4.84 |
50-day moving average | $1.74 |
200-day moving average | $1.58 |
Wall St. target price | $12.53 |
PE ratio | N/A |
Dividend yield | $0 (0%) |
Earnings per share (TTM) | $-1.58 |
Buy Adagene stocks from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Adagene stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Adagene price performance over time
Historical closes compared with the close of $1.554 from 2023-03-20
1 week (2023-03-14) | 8.67% |
---|---|
1 month (2023-02-22) | -10.17% |
3 months (2022-12-22) | 26.34% |
6 months (2022-09-22) | 13.43% |
1 year (2022-03-22) | -65.23% |
---|---|
2 years (2021-03-22) | -91.72% |
3 years (2020-03-18) | N/A |
5 years (2018-03-18) | N/A |
Adagene financials
Revenue TTM | $12.7 million |
---|---|
Gross profit TTM | $10.2 million |
Return on assets TTM | -26.15% |
Return on equity TTM | -55.96% |
Profit margin | 0% |
Book value | $2.60 |
Market capitalisation | $69.2 million |
TTM: trailing 12 months
Adagene share dividends
We're not expecting Adagene to pay a dividend over the next 12 months.
You may also wish to consider:
- Novo Nordisk A/S (NVO.US) (1.24% forward annual dividend yield)
Adagene share price volatility
Over the last 12 months, Adagene's shares have ranged in value from as little as $0.9 up to $4.842. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adagene's is 0.0692. This would suggest that Adagene's shares are less volatile than average (for this exchange).
To put Adagene's beta into context you can compare it against those of similar companies.
- Novo Nordisk A/S (NVO.US): 0.3095
- Regeneron Pharmaceuticals (REGN.US): 0.2094
- Alexion Pharmaceuticals (ALXN.US): 1.2595
Adagene overview
Adagene Inc. , a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China. .
Adagene in the news
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
Adagene Announces Poster Presentations on Anti-CTLA-4 SAFEbody®, ADG126, at Upcoming American Association for Cancer Research (AACR) Annual Meeting in April
Adagene Appoints Professor Aurélien Marabelle to Scientific and Strategic Advisory Board
Frequently asked questions
What percentage of Adagene is owned by insiders or institutions?Currently 10.676% of Adagene shares are held by insiders and 9.711% by institutions. How many people work for Adagene?
Latest data suggests 259 work at Adagene. When does the fiscal year end for Adagene?
Adagene's fiscal year ends in December. Where is Adagene based?
Adagene's address is: Building C14, Suzhou, China, 215123 What is Adagene's ISIN number?
Adagene's international securities identification number is: US0053291078
More guides on Finder
-
Treasury Bills
Treasury Bills are fixed-income assets with maturities of less than one year. Here’s what to know before investing.
-
How to buy Vanguard VTI Total Stock Market ETF units
Steps to investing in the Vanguard (VTI) Total Stock Market ETF.
-
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
-
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
-
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
-
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
-
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
-
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
-
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
-
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Ask an Expert